Hugo ten Cate


Prof. Hugo ten Cate graduated in Medicine at the University of Amsterdam in 1987. The title of his PhD thesis was 'Clinical and experimental studies with a low molecular weight heparinoid'. Hugo had his post-doctoral training at the laboratory of Prof. Robert Rosenberg and Dr Kenneth Bauer at the Beth Israel Hospital and Harvard Medical School Boston on mechanisms of inflammation associated coagulation activity (1988-1990). He completed his internal medicine training in 1996 and became a general internist in conjunction with research at Academic Medical Center (laboratory of Experimental Internal medicine, Prof. Pieter Reitsma). He received a Clinical Established Investigator grant from the Dutch Heart Foundation in 1998.

In 2002, Hugo ten Cate was appointed Professor of Clinical Thrombosis and Haemostasis at CARIM. In addition, Prof. ten Cate was appointed adjunct professor at the Center for Thrombosis and Haemostasis (CTH) at Gutenberg University Medical Center, Mainz, Germany in 2017

Since the transfer to CARIM in 2002 his research focus shifted from coagulation-inflammation research in sepsis models, to the broader field of cardiovascular (CV) disease (atherothrombosis and 'thrombo-inflammation'). A specific focus of current research is the pleiotropic actions of coagulation proteases in atherosclerosis, atherothrombosis and ischemia reperfusion injury. Clinical research is aimed at chronic thrombotic disease including peripheral artery disease, high risk patients with coronary disease on antithrombotic medication and, together with Dr Arina ten Cate-Hoek, on venous thrombosis and post thrombotic syndrome (PTS). He is workpackage leader in CVON consortia RACE-5 (coagulation and its impact on atrial fibrillation) and CONTRAST (acute ischemic stroke) and involved in the ITN consortia TAPAS and TICARDIO. His group has an ongoing target finding programme with Bayer (steered from CARIM by Dr Henri Spronk and Prof. Hugo ten Cate) as well as with 2M (on POC development).

Department of Biochemistry
Department of Internal Medicine
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: 4.344
T: +31(0)43 388 42 62

  • 2021
    • Jiritano, F., Fina, D., Lorusso, R., ten Cate, H., Kowalewski, M., Matteucci, M., Serra, R., Mastroroberto, P., & Serraino, G. F. (2021). Systematic review and meta-analysis of the clinical effectiveness of point-of-care testing for anticoagulation management during ECMO. Journal of Clinical Anesthesia, 73, [110330].
    • Olie, R. H., van der Meijden, P. E. J., Vries, M. J. A., Veenstra, L., van't Hof, A. W. J., ten Berg, J. M., Henskens, Y. M. C., & ten Cate, H. (2021). Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events. Netherlands Heart Journal, 29(10), 525-535.
    • Olie, R. H., Hensgens, R. R. K., Wijnen, P. A. H. M., Veenstra, L. F., de Greef, B. T. A., Vries, M. J. A., van der Meijden, P. E. J., ten Berg, J. M., ten Cate, H., Bekers, O., & Henskens, Y. M. C. (2021). Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients. Journal of Clinical Medicine, 10(17), [3992].
    • Giesen, P. L. A., Gulpen, A. J. W., van Oerle, R., ten Cate, H., Nagy, M., & Spronk, H. M. H. (2021). Calibrated automated thrombogram II: removing barriers for thrombin generation measurements. Thrombosis Journal, 19(1), [60].
    • ten Cate, H. (2021). Surviving Covid-19 with Heparin?New England Journal of Medicine, 385(9), 845-846.
    • Bruggemann, R. A. G., Alnima, T., Brouns, S. H. A., Hanssen, N. M. J., Schols, J. M. G. A., ten Cate, H., Spaetgens, B., & ten Cate-Hoek, A. J. (2021). A known unknown? Pharmacological prevention of venous thromboembolism in nursing home residents. Journal of the American Geriatrics Society.
    • Ten Cate, H., Guzik, T. J., Eikelboom, J., & Spronk, H. M. H. (2021). Pleiotropic actions of factor Xa inhibition in cardiovascular prevention - mechanistic insights and implications for anti-thrombotic treatment. Cardiovascular Research, 117(9), 2030-2044.
    • ten Cate, H., & Lammle, B. (2021). Special Issue: "The Latest Clinical Advances in Thrombocytopenia". Journal of Clinical Medicine, 10(16), [3463].
    • Aarsetøy, R., Ten Cate, H., Spronk, H., Van Oerle, R., Aarsetøy, H., Staines, H., & Nilsen, D. W. T. (2021). Activated factor XI-antithrombin complex presenting as an independent predictor of 30-days mortality in out-of-hospital cardiac arrest patients. Thrombosis Research, 204, 1-8.
    • Dahlen, B., Schulz, A., Göbel, S., Tröbs, S-O., Schwuchow-Thonke, S., Spronk, H. M., Prochaska, J. H., Arnold, N., Lackner, K. J., Gori, T., Ten Cate, H., Münzel, T., Wild, P. S., & Panova-Noeva, M. (2021). The impact of platelet indices on clinical outcome in heart failure: results from the MyoVasc study. Esc heart failure, 8(4), 2991-3001.